

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

- (51) International Patent Classification⁷: **A61K 45/06**
- (21) International Application Number: **PCT/EP01/06976**
- (22) International Filing Date: **20 June 2001 (20.06.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP
- (71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).
- (71) Applicants and
(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-**
tin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-**
AUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonnier et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either *Flt1* or *Flk1/KDR* gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that *Flk1/KDR* knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas *Flt1* deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the *Flt4* gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of *Flt4* for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of *Flt4* in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in *Tie1* die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The *Tie2* knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the *Tie2* ligand *Ang1*, as well as overexpression of *Ang2*, an inhibitory ligand, resulted in phenotypes similar to the *Tie2* knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of *Ang1* (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., *Nature Med.* 1, 1024-1028, 1995; Benjamin et al, *Development* 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendoneothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, *Science* 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., *Cancer Res.* 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., *Nature* 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., *Nature* 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., *Proc. Natl. Acad. Sci. USA* 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., *Cancer Res.* 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I



20 in which


r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

25


R₃ und R₄ a) each independently from each other have the meaning
 of lower alkyl,

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa (-O-), thia (-S-) or imino (-NH-),

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one or more N-atoms carry
an oxygen atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning

of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or upto two of the groups R_a-R_f form a bridge witheach up to 3 C-atoms with R^1 or R^2 ,has the meaning of group $=NR^9$ or $=N-$,has the meaning of group $-(CH_2)_p$,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally

substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is

optionally substituted by one or more of halogen,

or is unsubstituted or substituted aryl or

heteroaryl,

has the meaning of hydrogen or C_{1-6} -alkyl, orform a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

has the meaning of monocyclic or bicyclic aryl or

heteroaryl which is unsubstituted or optionally

substituted with one or more of fur halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

independently from each other have the meaning

of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or

5

10

X

Y

p

 R^1

15

 R^2


20

 R^3

25

 R^4, R^5, R^6 and R^7

C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




5 R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




15

in which



R¹

has the meaning of group





20




14



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$


in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



and

10

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

15

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.
Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv)

specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to
15 coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various
20 modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a
5 volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF
10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

30

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
20
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

25

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

30

41



I,

in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

10

a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,



II,

15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20




has
 5 G wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;
 10 has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2-$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),
 15 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,
 20 Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R_1 and R_2 independently from each other have the meaning of H or lower alkyl,
 X has the meaning of imino, oxa or thia;
 25 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,
 30 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

10

A

has the meaning of group $=NR^2$,


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z


has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group

15



or A, Z and R^1 together form the group

20



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

X

Y

P

R¹

R²

R³

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7


substituted with one or more of $\text{f}\ddot{u}\text{r}$ halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R^1 has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$


in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5



Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaca gccaaaaaac cataatggtg ccacagggat ggagcagga agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgtgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaacc caaaaacgca acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gagcatagcg acatcacgtg cggtttttta atgtccctgg tggcgatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggagaca 1080
tccgccaag tcctccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtccacagg ctgggctgcc gtcccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatatat ggcaatttta tattccacag 1260
tcagggtggg ctgcatagc tcatttaatg ttaaaccgca tcaggggctt ctctcccggt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggg 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggctcgc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgttag gccgtgctgt ctggggctcg aggtcttttc tgctgggtgt 1620
cttggacggg cgggtagttc tgctgcagag acaaaagcat tccccctccc ttccgggctg 1680
atthttgggt attcatatct acgccagagt ccaaactggc atcattactt ccgttcttcc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct cttaagaccc ctggggcctg tgctaccag 60
 acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tectgtggcc cattagggaa gtggtgacct cgggagctat ttgectgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccg ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

25 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 ttgttaagct tegtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tectgcgcat tgcaggtctg tgcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaaatactt ttctctggat ctactcatg 480
 atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

40 cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt ctctctcgtg gggcgagaga caaagcagtc cacgaggtag gggcagggtg 360
 ctcgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgca gaacactggc gacataggtg cccatcagtg 480
 ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
 cggccgcccag cgcccgtctc acctgtgggt ccttggccgg cagtggcccg agctccccct 600
 50 ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 ggggtgggtg gctgacgaag aggaactgca gcaccagta gcggatgtgg gagatgggga 720
 aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggctcagtg ctcttgacc tggctcagca 900
 55 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcaggggag 1020
 gtctgccacg cccgttctac cgctgcctg ccgggcgggc caggtggagg tggggacgat 1080
 ggccggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgc	ttttgaaaat	gttgaggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccct	ggttcgcaca	tgtacaggaa	tgggacccag	180
	ttggggcaca	gccatggact	tccccgcct	ggaatgtgtg	gtgcaaagtg	gggccagggc	240
5	ccagacccaa	gaggagaggg	tgggtccgag	acacccccgg	atgtcagcat	ccccgcacct	300
	gccttctggc	ggcacctccc	gggtgctgtg	ttgagtcagc	aggcatgggg	tgagagcctg	360
	gtatatgctg	ggaacagggg	gcaggggcca	agcgttcctc	cttcagcctt	gacttggggc	420
	atgcaccccc	tctcccccaa	acacaaaaca	gcacttctcc	agtatgggtg	caggacaggt	480
	gtcccttcag	tcctctggtt	atgacctcaa	gtcctacttg	ggccctgcag	cccagcctgt	540
10	gttgtaacct	ctgcgtcctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttgctttatc	acttctaaga	cattttgtac	ggcacggaca	agttaaacag	660
	aatgtgcttc	cctccctggg	gtctcacacg	ctccacagag	aatgccacag	gggccgtgca	720
	ctgggcaggc	ttctctgtag	aaccccaggg	gcttcggccc	agaccacagc	gtcttgccct	780
	gagcctagag	cagggagtc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
15	accaaaggcc	tcctgttctg	ttatttctg	tataatcaaca	tgctattttg	ttttcactca	900
	cttctgactt	tagcctcgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgctagtt	960
	acgtttttct	tcttacacat	gaaaataaat	gcataagtgt	tagaagaaaa	aaaaa	
	<210>	6					
20	<211>	2313					
	<212>	DNA					
	<213>	Human					
	<400>	6					
25	ccagagcagg	cctggtggtg	agcagggagc	gtgcaccgga	cggcgggatc	gagcaaatgg	60
	gtctggccat	ggagcacgga	gggtcctacg	ctcggggcgg	gggcagctct	cggggctgct	120
	ggattacct	gcgtacttc	ttcctcttcg	tctccctcat	ccaattcctc	atcatcctgg	180
	ggctcgtgct	cttcattggtc	tatggcaacg	tgcagtgag	cacagagtc	aacctgcagg	240
30	ccaccgagcg	ccgagccgag	ggcctataca	gtcagctcct	agggctcacg	gacctccagt	300
	ccaacttgac	caaggagctc	aacttcacca	cccgcgccaa	ggatgccatc	atgcagatgt	360
	ggctgaatgc	tcgcccgcgac	ctggaccgca	tcaatgccag	cttcgccag	tgccaggggtg	420
	accgggtcat	ctacacgaac	aatcagaggt	acatggctgc	catcatcttg	agtgagaagc	480
	aatgcagaga	tcaattcaag	gacatgaaca	agagctgcga	tgccttgctc	ttcatgctga	540
	atcagaaggt	gaagacgctg	gaggtggaga	tagccaagga	gaagaccatt	tgcactaagg	600
35	ataaggaaag	cgtgctgctg	aacaaacgcg	tggcggagga	acagctgggt	gaatgcgtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaactgc	aaaaggtgca	720
	agccctctgc	ctgcccctgg	acaaggacaa	gtttgagatg	gaccttcgta	acctgtggag	780
	ggactccatt	atcccacgca	gcctggacaa	cctgggttac	aacctctacc	atcccctggg	840
	ctcggaattg	gcctccatcc	gcagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
40	ggtggaggag	ctggcccggg	gcctccgggc	ggatatcgaa	cgcgtggccc	gcgagaactc	960
	agacctccaa	cgccagaagc	tggaaagcca	gcagggcctg	cgggccagtc	aggaggcgaa	1020
	acagaaggtg	gagagggagg	ctcaggcccg	gcagggccaag	ctccaagctg	aatgctcccc	1080
	gcagaccag	ctagcgctgg	aggagaaggc	gggtgctgcg	aaggaaacgag	acaactctggc	1140
	caaggagctg	gaagagaaga	agagggaggc	ggagcagctc	aggatggagc	tgcccatcag	1200
45	aaactcagcc	ctggacacct	gcatcaagac	caagtcgcag	ccgatgatgc	cagtgtcaag	1260
	gcccattggg	cctgtcccca	acccccagcc	catcgaccca	gctagcctgg	aggagttcaa	1320
	gaggaagatc	ctggagtccc	agaggccccc	tgcaggcatc	cctgtagccc	catccagtgg	1380
	ctgaggaggc	tccaggcctg	aggaccaagg	gatggcccga	ctcggcggtt	tgccggaggat	1440
	gcagggatat	gctcacagcg	cccgacacaa	ccccctcccg	ccgcccccaa	ccacccaggg	1500
50	ccaccatcag	acaactccct	gcatgcaaac	ccctagtacc	ctctcacacc	cgcaaccgcg	1560
	cctcacgatc	cctcaccag	agcacacggc	cgcgagatg	acgtcacgca	agcaacggcg	1620
	ctgacgtcac	atatcaccgt	ggtgatggcg	tcacgtggcc	atgtagacgt	cacgaagaga	1680
	tatagcgatg	gcgtcgtgca	gatgcagcac	gtcgacacac	gacatgggga	acttggcatg	1740
	acgtcacacc	gagatgcagc	aacgcagtc	cgggccatgt	cgacgtcaca	catattaatg	1800
55	tcacacagag	gcggcgatgg	catcacacag	acggtgatga	tgctcacacac	agacacagt	1860
	acaacacaca	ccatgacaac	gacacctata	gatattggac	caacatcaca	tgcaacgcatg	1920
	ccctttcaca	cacactttct	acccaattct	cacctagtgt	cacgttcccc	cgaccctggc	1980
	acacggggcca	aggtagccac	aggatcccat	ccccctcccg	acagccctgg	gccccagcac	2040
	ctccccctct	ccagcttcc	ggcctcccag	ccacttctc	acccccagtg	cctggacccg	2100
60	gaggtgagaa	caggaagcca	ttcacctccg	ctccttgagc	gtgagtggtt	ccaggacccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtc	cctgtgtcgc	ggaggggagc	cactccttct	2220
	cccccaactc	ccagccctgc	ctgtggcccg	ttgaaatgtt	ggtggcactt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			
65	<210>	7					
	<211>	389					

<212> DNA
<213> Human

<400> 7

5
gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcaccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tttttcgga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

15
<210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

20
tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tttttg

25
<210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagacc agcagagaaa gaattctgaa ttccccttgc 120
35 tgaactgaac tattctgtta catatggttg acaaactctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttoga tgatgaacat 240
tctgtatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tttttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
40 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480
ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

45
<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgcct gatggcataa tccgggtgca acccaaactc 240
55 gagtcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtcgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
ggtgtcatgt cctctttttt gccttggtta ttgtgttacc ttccagccaa gggttgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaactag 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgtttaa agaaagtgg gatagctttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctacagctaat ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatatttt 1080
 gtatatacaa taatatattgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaaatat tatactaata tgttgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgttaag actctgattt ccctttggac 1260
 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataattta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 10 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcagggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cgggtgagaca agtgcccgac 120
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgta 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcggccg cgaccacgct gggtagcga
 25 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 ccagaaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa taaaaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 40 taggataaca ggtctgcctg tttgaagatg aaaaaataata cccattttaa atttgcccta 480
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaagggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 45 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960
 ataagagttc ttttgatgac g
 50 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctccccc agagcgaccc cccgggcagg tcggggccca agaatgacc cagcaactgc 180
 tccctacca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtgggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t
 65 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacaggtt gagtagagca acaacaacaa aagccttatgc agtcaccttc 120
 10 tttgaaaatg ttaaatacaa gtccatttct ctttgtccag ctgggttttag ctgaggttag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
 gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
 taaaagtcat ttttactgtt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gactgatttt 420
 15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
 tactgaaaac aatgggtgcca tatgtcccaa agacatttcc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaatgga gtagtaacca agcttttctg cccaggaagt acaaacatc 660
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
 20 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
 acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
 attcattata atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaatccct 900
 gcctatgttc tcagatatcc tgggttaggtc aggagtggga acccaaaatc aattctttta 960
 acaaacacta aagggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgagggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat taccctatct 60
 ataattattcc tatttctaatac tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
 35 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
 aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtggt tgtaagcac 240
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
 <211> 2041
 <212> DNA
 <213> Human

<400> 16

45 cccccgcag aactcccccc tgggaatagga tttttaaaac ccttgacaat tagaaatcct 60
 atagagggtta gcattttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
 cttaaaaccaa attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
 atacagacac agtgaatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
 50 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
 ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
 caggtagcata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
 55 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
 ataaaaacaa gcaatgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660
 tagatatattg ttatagtctg acattttaac atactatagta tttagcgttt cgtgaccagt 720
 gcattttgga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctcctcc 780
 accccctcca ccagttgggc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
 60 ttctgtgtaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tctgaatttt 1080
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa accattctt 1140
 ttgacatttc cttatttttc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
 65 gtaaatgact ctgggaggat gctaattgca gagcctcaga ctgggtgtac atctgatatg 1260
 aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caatthttgtg	caggaagctt	1380
	catcagtcce	tgaaggcttt	aatttttttag	caaggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
5	ccaaaaccag	tggccagtg	tacattgtct	aaaattttcc	ttctcacatg	atactttctga	1560
	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttccctccgt	gattttgcata	1620
	gtttttctcag	catttttgca	agaggcacag	ttttcacaat	aattattggtt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggtg	tggtttcacc	1740
	tcccggtttc	tgaggtacat	ctttattaac	agaatcttg	ttagattcgt	tagggacaga	1800
10	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atgggtttttt	cattcacaaag	1860
	tgagtcacag	atgaaggcag	ctgttggttg	attataaact	actggctctt	ctgaaggacc	1920
	gggtacagac	gcttgcat	gaccaccatc	ttgtatactg	ggtgatgatg	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
15	<210>	17					
	<211>	235					
	<212>	DNA					
	<213>	Human					
20	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
	acctctacaa	ataaaaaatt	aaaaaattag	ccaggtgtgg	cagcgaacaa	ctgtagtctc	120
25	agatactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aaggttacag	180
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	
	<210>	18					
	<211>	2732					
	<212>	DNA					
30	<213>	Human					
	<400>	18					
35	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgctggct	60
	tcatgttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttggtga	tcacattgtg	caaaatgggtg	aagcattcaa	acactttgaa	180
	accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcgtt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggtccctttg	gttgcttttt	attaatgagg	agactattgt	300
40	gatggcatat	ctcttcacta	tatttaattgc	tttccaggga	gtgttcattt	tcatctttca	360
	ctgtgctctc	caaaaagaa	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgtctgc	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
45	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgtg	cacaaggggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
50	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
	ctattgtggc	agatgcttca	tctttaattgc	acagcgacaa	cccagggtctg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagaggctg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatag	aagcatgccc	aatcttagag	1200
55	actctcccta	tccggagagc	agccctgaca	tggagaaga	cctctctccc	tccaggagga	1260
	gtgagaatga	ggacattttac	tataaaagca	tgccaatctc	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatgggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctggtt	acaagtcttt	1440
	aatcatacag	ctaaggaatt	ccaagggcca	catgcgagta	ttaataaata	aagacaccat	1500
60	tggcctgacg	cagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtggttctc	1560
	tggtgtaaaa	aagatgactg	aaccttgcag	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgtatat	acacagagta	tactaaaagt	aattatttgt	tacaaagaaa	agagatgcca	1680
	gccagggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	ttttagggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
65	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgagttc	actgcaaata	ttttacatta	aggcaaagat	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttcctcaa	ctgtacaatg	aactattctc	2040
	atgaaaaatg	gctaaagaaa	ttatatatttg	ttctattgct	agggtaaaat	aaatacattt	2100
	gtgtccaact	gaaatataat	tgctattaaa	ataattttta	agagtgaaga	aaatattgtg	2160
5	aaaagctctt	ggttgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactcattt	tcacttcttt	tccactgtat	acagtgttct	gctttgacaa	agtttagtctt	2280
	tattacttac	atttaaattt	cttattgcca	aaagaacgtg	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgtg	gaaatctaga	aaagattgtg	2400
	tgtaacccct	gtttattctt	gaacagaggg	caaagagggc	actgggcact	tctcacaaac	2460
10	tttctagtga	acaaaaggtg	cctatttctt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attccttctg	cctatattta	gtaattaatt	tattttatga	taaagttcta	2580
	atgaaatgta	aattgtttca	gcaaaattct	gctttttttt	catccctttg	tgtaaacctg	2640
	ttaataatga	gccccatcact	aatatccagt	gtaaagttta	acacgggttg	acagtaaata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccccataat	gatttttaaaa	taaattggat	aaacatatga	tataaagtgg	gtactttaga	60
	aaccgccttt	gcataattttt	tatgtacaaa	tctttgtata	caattccgat	gttccttata	120
25	tattccctat	atagcaaacc	aaaaccagga	cctcccaact	gcatgcctca	agtcctctgtg	180
	gagcactctg	gcaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaatt	aaatacctcg	gccgcgacca	cgctgg			
	<210> 20						
	<211> 2361						
30	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cgtgggccct	gcttcgcttt	tgagggccat	aagctcattg	60
	cccactgggt	tagaggctac	cttatcattg	tctcccgtga	ccggaagggt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattctaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagtggat	gtgcttgctg	240
40	agtggggctc	cctgtacgtg	ctgacgcggg	atgggcgggt	ccacgcactg	caggagaagg	300
	acacacagac	caaactggag	atgctgttta	agaagaacct	atgtgagatg	gcgattaacc	360
	ttgccaaagag	ccagcatctg	gacagtgaat	ggctggccca	gattttcatg	cagtatggag	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatatc	cgaaccattg	480
	gaaagttgga	gccatcctac	gtgatccgca	agttttctgga	tgcccagcgc	attcacaacc	540
45	tgactgccta	cctgcagacc	ctgcaccgac	aatccctggc	caatgccgac	cataccaccc	600
	tgctccctcaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaagtc	cactttgatg	tgagagacagc	catcaaggtc	ctccggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcat	gagtggatcc	780
	tgaagatcca	ctctagaagac	attaagaatt	atcaggaagc	ccttcgatac	atcggcaagc	840
50	tgcccttttga	gcaggcagag	agcaacatga	agcgtacgg	caagatcctc	atgcaccaca	900
	taccagagca	gacaactcag	ttgtgaagg	gactttgtac	tgattatcgg	cccagcctcg	960
	aaggccgcag	cgatagggag	gccccaggct	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgccaa	taaccgcgca	gagctgaaag	ccttcctaga	gcacatgagt	gaagtgcagc	1080
	cagactcacc	ccaggggatc	tacgacacac	tcttgagct	gcgactgcag	aactgggccc	1140
55	acgagaagga	tccacaggtc	aaagagaagc	ttcacgcaga	ggccatttcc	ctgctgaaga	1200
	gtggctcgctt	ctgcgacgtc	tttgacaggt	ccctggctct	gtgccagatg	cagacttcc	1260
	aggatggtgt	cctttacctt	tatgagcagg	ggaagctgtt	ccagcagatc	atgcactacc	1320
	acatgcagca	cgagcagtac	cggcaggtca	tcagcgtgtg	tgagcgccat	ggggagcagg	1380
	acccctcctt	gtgggagcag	gccctcagct	acttcgctcg	caaggaggag	gactgcaagg	1440
60	agtatgtggc	agctgtcctc	aagcataatc	agaacaagaa	cctcatgccca	cctcttctag	1500
	tggtgcagac	cctggcccac	aactccacag	ccacactctc	cgatcatcagg	gactacctgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctgcgg	gtgcggcggt	1620
	accgagagga	gaccaccggt	atccgccaag	agatccaaga	gctcaaggcc	atgcctaaga	1680
	ttttccaaaa	gaccaagtgc	agcatctgta	acagtgccct	ggagttgcc	tcagtccact	1740
65	tctgtgtgtg	ccactccttc	caccaacact	gctttgagag	ttactcggaa	agtgatgctg	1800
	actgccccac	ctgcctccct	gaaaaccgga	aggtcatgga	tatgatccgg	gcccggaac	1860
	agaaacgaga	tctccatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

5	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagcctgg	aggctgggct	gcaacgcgac	ctactcatgc	2040
	actccaggag	gggcacttaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaacagaca	caatgggacc	tgggcggggc	ttacacagaa	ggctggctga	catgcccagg	2160
	gctccactct	catctaattg	cacagccctc	acaagactaa	agcggaactt	tttcttttcc	2220
10	ctggccttcc	ttaatttta	gtcaagcttg	gcaatccctt	cctctttaac	taggcagggtg	2280
	ttagaatcat	ttccagatta	atggggggga	aggggaacct	caggcaaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
	<210> 21						
	<211> 179						
15	<212> DNA						
	<213> Human						
	<400> 21						
	aggtgttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaatg	gattcttttta	60
20	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agttgaagga	aattgaaagg	aaaaaattag	aactaatgc	
	<210> 22						
	<211> 905						
	<212> DNA						
25	<213> Human						
	<400> 22						
30	tttttttttt	ttctttaacc	gtgtgggtctt	tatttcagtg	ccagtgttac	agatacaaca	60
	caaagtgtcc	agttagaagg	aattcaaacg	gaatgccaa	gtccaagcca	ggctcaagaa	120
	ataaaaagg	aggtttgagg	taatagataa	gatgactcca	atactcactc	ttcctaagg	180
	caaagggtact	tttgatacag	agtctgatct	ttgaaactgg	tgaactcctc	ttccacccat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttaaaattt	gtggtgggaa	300
35	taggggtcatt	aataactatg	aataatctct	ttagaagggtg	accattttgc	actttaaaagg	360
	gaatcaattt	tgaaaatcat	ggagactatt	catgactaca	gctaaagaat	ggcgagaaa	420
	gggagctgga	agagccttgg	aagtttctat	tacaaaataga	gcaccatata	cttcatgcca	480
	aatctcaaca	aaagctcttt	tttaactccat	ctgtccagtg	tttacaata	aactcgcaag	540
	gtctgaccag	ttcttggtaa	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
40	cagaaaaggc	taccaggagc	ctaattgcctc	tttcaaacat	tgggggaacc	agtagaaaa	660
	ggcaggggtc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gttaaaagt	720
	cctgaagatg	gtaaccagc	tagtgaggaa	ttaatacccc	accttgccca	gtccacagag	780
	aaacaacagt	agaaagaagg	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
45	ggtctcttct	ttcctttttt	tttttccaaa	agtgttcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctattttat	atgcaattcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaagt	aaatgtataa	aaataaatat	gttattatag	gcatttatta	ctaactatag	180
	tccttcttgg	aaggaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagtaaca	240
	tattttacta	tatacatatg	gaaaaaatca	tattctcaca	gaagagctga	acagacattc	300
50	accaggatac	gactgttgga	ccagctgctg	gagatggacc	tgctacccct	cagcagcctc	360
	cccaccacaa	gacaagtgat	ctcaatgtcc	ccaaacctgt	gggaccctgt	tctacacacc	420
	tcatttttgt	tccggcggtt	catcctcctt	gtgtgattgt	actgattttc	atgagacaca	480
	agttacttct	ttacatccat	attcccaaag	cagggttaca	tggtaggaaa	gaaaggaagt	540
	tggaggtact	aagctcattg	tgtctcctct	agcttttacc	agcatcta	gcttcaactgc	600
55	tttttttcca	ttgtagactt	taatgcactt	gaataaatat	atggagtgtg	tttttcttca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaagagga	agccatttgc	720
	gttatttcac	gttgctgagc	ctttctctca	tgttgaacaa	tctgaagttt	taattctcgg	780
	tagaaataat	gtataaacat	tctctgaaac	catagcagcc	ataaacagt	ctgggtcaag	840
	atcctatttg	tactcctttc	ttccccccat	gttagtgagg	taaagtaaaa	caggtcttag	900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctcactt tgccctggcc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 10 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggtagaca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taattttagg tcgaagggca ttgccacag 1740
 15 taagaacctg gatgggtcaa ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggt tccgctgttt cacttcgatg ttggtggctc 1980
 20 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 tttttttaca agtagatcca ttccccccgc aaacaccaca tttatcaaac ttcttttttg 2100
 agtctatgat gcgatcaca ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgcttttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaaggca agacaaatgg cctcttgtag tgaatacttc ggcaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata ttgttagagc ttgctagaa tggattacat 420
 ggtagtgatg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540
 40 aaagctttgt ctaaaaattt ggcctaggaa tggttaacttc attttcagtt gccaaaggggt 600
 agaaaaataa tatgtgtgtt gttatgttta tgtaaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc ctgaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa ttatagacc agctaaatcc ctaacttga 840
 45 tctggaatgc attagttagt ccttgtagca ttcccagaat ttcaggggca tctggtgttt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctatttgtg taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcattctat ggaaactcct gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtgaata tgaatgcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tatttttaaa ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65

gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttcccctc actgtcattg gaggcatctt 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgactca cctacttcca gttgtctggg gaggattacc gctgggtgtg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttcctctact cagttttcta 480
 ttatgcccgg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540
 cttactcaact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcctt 600
 aaagttcatc cggatatatc atgttaacct caagatggac tgagttctgt atggcagaac 660
 tattgtgtt ctctcccctt cttcatgccc tgttgaaact tcctaccagc ttctctctctg 720
 attgactgaa ttgtgtgatg gcattgtgtc tctccctttt tcccttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 taagttgcct ttagtttttg tcctgatttt tctttttaca attaccaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

20 <210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29

30 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggcttcagt ccgtgtgggg 180
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaag acgtcatcaa tgaaggtgtt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaaagagc tggggcagca tgaagaggaa accaaaggca tagacccctg tgacgaagct 480
 35 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 cccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600
 ctcggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcactttca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 40 cacgggtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840
 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaaccgaa ctgctgcagg gactacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gcccagtgta gacctgtcgt taggacacgg tgaggggcag 1080
 45 ctcggtggtg gagcggttta tgaccatcag gtccttcacg cgggtgtcga gctggtcgat 1140
 gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200
 cacatcggca ggcaggggagg acccggtcaaa gacaaagtgt tccgccatca cgttcagcgc 1260
 cagcgcgggt cgccagtggg acactggctc atccagggca ctgctcggtt tcttctccgc 1320
 ctcgatctgc tgtgtatcag actcccgtt gagcaggttg atttcttctg gcttggggac 1380
 50 catgtaggtg gtcagaggac tgaccaggtg cacctgcttc ccgtcgtgcc acggcaggac 1440
 cccagcgtga tggaggaaga ttaggcata cagcgtccca ttgtttctcg ttttctttgg 1500
 tacagaaaca ttaactgtcc tttcaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgccgag ccaggtaggg ctggatgcag ttggcgctgc cggagcacgg 1680
 55 gcgggtgtag acgatgccgt acatgaccca gcagggtgac accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgag gcccc

60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

5 acaccatcta cgggcacccat ggaactgctt caagtgaacca ttctttttct tctgcccagt 180
 atttgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttgtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgttttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaa 540
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtagatta 600
 10 acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggcactgag 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tttttgccc 720
 gtgggtattg ctttgattgt aataacactt tcagtatttg ttctgggtggg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 15 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcataat 960
 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgaact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tctgtttctc 1140
 tcacatttaa aaattccatt actccattta caggagcggt cctaggaaaa ggaatttttag 1200
 gaggagaatt tgtgagcagt gaatctgaca gcccaggagg tgggctcgt gataggcatg 1260
 20 actttcctta atgtttaaag ttttcgggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg ttgtcttata ttacctactg ttgtttacca ctatgttaat 1380
 gcagggaataa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgtacttt 1440
 gtacatataa gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
 25 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa

<210> 31
 <211> 750
 <212> DNA
 <213> Human

30
 <400> 31

35 cacttgggca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatccctttt ggccctcttt ggagcatgcc ttccctatct tatccttggc 180
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240
 aacagccttt ccctaattgg aaaatgcagt cctgttttaa acctttgatt tacgactact 300
 40 tgtacatgct tgctcattac aattttgaca ttttttacat agtgaagacc ccaaacatat 360
 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagtatac 480
 ttttaatagc ttcctcagca cactatttcc catgcattaa atatgataaa ataactatc 540
 actgcccatac ggtcttgtaa aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggaact cctgacaggt 660
 45 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgtcac caccgtcccc

<210> 32
 <211> 1620
 <212> DNA
 <213> Human

50
 <400> 32

55 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60
 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga tacctgcctt atgtggattc tttccacac tgctttcatt 240
 ttttaagtata aagacttaga aaactagaat aatgtcttta caaataatta aaagtatgtg 300
 60 atgttctggg ttttttccct ctttttagaa cccgcctcc atttaaaaaa ttaaaaaaaa 360
 aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttcactta ttccaggaca 420
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540
 gggttagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagt 600
 attggaatgg cacaggaaac cgaatcacat ggggtgccct cccttgggtt tcaagtatct 660
 65 tggagttgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttaa acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttggtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgcccaaaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtcttttgga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaattctg	tgcaaaactct	gatgatacct	gcttatgtgg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaaacta	gaataatgct	1260
10	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaacctgtg	1320
	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaata	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tccctctgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	aggggtattat	atatataaat	1560
15	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
	<210>	33					
	<211>	2968					
	<212>	DNA					
	<213>	Human					
20							
	<400>	33					
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
25	gaggagggaag	aagagggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaaag	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgatc	ggactaaaga	agaaagggtc	tatgacaaa	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
30	gtacttgggc	atgtggacac	aggggaagaca	aaaattctag	ataagctccg	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcatgg	tttggagccc	660
35	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgcactc	720
	aataagattg	atagggtata	tgattggaag	aagagtcctg	actctgatgt	ggctgtctat	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttggtacc	tacctctgca	catactgggtg	atggcatggg	aagtctgac	960
40	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaaa	ctgtgaagag	1020
	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaagggaagga	gatacaatca	ttgttccctg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctcctc	ctatgaagga	attacgatgt	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattctttga	1260
45	aaagacctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaattttctg	aaacatcaga	agtgccttat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
50	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagtgt	aggagttaga	1620
	attttttagt	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacggtggaa	1800
	gcaggtcagg	tgaaacaggg	gacacccatg	tgtgtcccaa	gcaaaaattt	tggtgacatc	1860
55	ggaatagtaa	caagtattga	aataaacatt	aaacaagtgg	atggtgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaataga	acctatccct	gggtgagtcac	ccaaaatggt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtcatttga	tgcaactcaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcactctaatt	ttttcacatg	gagcaggaac	tggagtaaat	gcaatactgt	2160
60	gttgtaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tgggaaggag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgtttttaag	tttgccttc	2400
	cccaaatttg	gatttttatt	acagatctaa	agctctttcg	atattatact	gattaaatca	2460
65	gtactgcagt	atttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gcctttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

	agctgctttg	tgtgaaacca	tggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccattgtaat	catcacaatt	ctaaacaaaa	ctaccaataa	agaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatgggta	gtggtagctt	ctctcccaca	2820
5	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
	ggatgcccag	cacctgggta	acagtaggag	attttatata	ttaatctgat	ctgtttaatc	2940
	tgatcggttt	agtagagatt	ttatacat				
	<210>	34					
	<211>	6011					
10	<212>	DNA					
	<213>	Human					
	<400>	34					
15							
	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgcac	tccgagcggg	60
20	accgccccgg	actccccctc	gggcccggca	ctcagaggag	gaggagagag	gccgcccggc	120
	cggcttgagc	cgagcgcagc	accccccgcg	cccccgccca	gaagtttggt	tgaaccgggc	180
	tgccgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cgccccaaag	ctcgtgggct	cggggtcgcg	cgcccgacga	agggcgggg	300
	tccgcccgcg	aggggaggcg	ccccggggga	cccagagagg	gggtgaggac	cgcgggctgc	360
25	tggtgcggcg	gcggcagcgt	gtgccccgcg	caggggaggc	gccgccccgc	ttccggcccc	420
	gctgcgagga	ggaggcgggc	gcggcgaggg	aggatgtact	tggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctgggtctcg	ctgctggggc	tgctgctgct	gccggcgccg	540
	tccggcaccc	gggcgctggg	ctgcctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
	aaccgcccgg	ggagcatcgt	gcagggcgtc	tgcggctgct	gctacacgtg	cgccagccag	660
30	gggaacgaga	gctgcggcgg	caccttcggg	atttacggaa	cctgcgaccg	ggggcgctgc	720
	tgtgtcatcc	gccccccgct	caatggcgac	tcctcaccg	agtacgaagc	gggcgtttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttggtttta	aaccatgcaa	tgaaaacctt	840
	attgctggct	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
	aatccctttg	agttttccaa	tcaggatatg	tgcccttcag	ctttaaagag	aattgaagaa	960
35	gagaagccag	attgtcccaa	ggcccgtctg	gaagtccagt	tctctccacg	ttgtcctgaa	1020
	gattctgttc	tgatcgaggg	ttatgctcct	cctggggagt	gctgtccctt	accagccgcg	1080
	tgctgtgtgca	accccgagg	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtctgt	acctctatga	gtgcaaacca	1200
	gttttcggcg	tggactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgctgtccc	1260
40	ccggacagct	atgaaactca	agtcagacta	actgcagatg	gttgctgtac	tttgcaaca	1320
	agatgcgagt	gtctctctgg	cttatgtggt	ttccccgtgt	gtgaggtggg	atccactccc	1380
	cgcatagtct	ctcgtggcga	tgggacacct	ggaaagtgtc	gtgatgtctt	tgaatgtgtt	1440
	aatgatacaa	agccagcctg	cgtatttaac	aatgtggaat	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcgggt	ctgtcgatgc	caagggggcg	ttgccatctg	cttcaccgcc	1560
45	cagtgtgggtg	agataaactg	cgagaggtag	tacgtgcccg	aaggagagtg	ctgcccagtg	1620
	tgtgaagatc	cagtgtatcc	ttttaataat	cccgtgggt	gctatgccaa	tgccctgac	1680
	cttgcccacg	gagaccgggtg	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggt	1740
	gaacgccact	gcgttgcgac	cgtctgcgga	cgacctgca	caaaccctgt	gaaagtgcct	1800
	ggggagtggt	gcccgtgtgt	cgaagaacca	accatcatca	cagttgatcc	acctgcagt	1860
50	ggggagttat	caaactgcac	tctgacacgg	aaggactgca	ttaatgggtt	caaacgcgat	1920
	cacaatgggt	gtcggacctg	tcagtgcata	aacaccaggg	aactatgttc	agaacgtaaa	1980
	caaggctgca	ccttgaactg	tccttcgggt	ttccttactg	atgccccaaa	ctgtgagatc	2040
	tgtgagtgcc	gcccaggcc	caagaagtgc	agaccataa	tctgtgacaa	gtattgtcca	2100
	cttgattgca	tgaagaataa	gcacggctgt	gacatctgtc	gctgtaagaa	atgtccagag	2160
55	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtcttate	2220
	tgcaagtgca	gagaggcctc	tgcttcagct	gggccacca	tcctgtcggg	cactgtcttc	2280
	accgtggatg	gtcatcatca	taaaaatgag	ggagactggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgcc	ctgatcacct	gcccggtgcc	tgccgtgggc	2400
	aacccaccca	ttcacctgg	acagtgtgtc	ccatcatgtg	cagatgactt	tgtggtgcag	2460
	aagccagagc	tcagtactcc	ctccatttgc	cacgcccctg	gaggagaata	ctttgtggaa	2520
60	ggagaaacgt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgctg	2580
	tgtgagacag	aggtgtgccc	accgctgtct	tgccagaacc	cctcacgcac	ccaggattcc	2640
	tgctgcccac	aggtgtacaga	tcaacctttt	cggccttcct	tgtcccgcaa	taacagcgta	2700
	cctaattact	gcaaaaaatga	tgaaggggat	atatctctgg	cagctgagtc	ctggaagcct	2760
	gacgtttgta	ccagctgcat	ctgcattgat	agcgtaatga	gctgtttctc	tgagtcctgc	2820
65	ccttctgtat	cctgtgaaaag	acctgtcttg	agaaaaggcc	agtgttgtcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtgggtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

	gagcgggtggg	accttgacag	ctgcacccac	tgctactgcc	tgacgggcca	gaccctctgc	3000
	tcgaccgtca	gctgcccccc	tctgccctgt	gttgagccca	tcaacgtgga	aggaagttgc	3060
	tgcccaatgt	gtccagaaat	gtatgtccca	gaaccaacca	atatacccat	tgagaagaca	3120
5	aaccatcgag	gagaggttga	cctggagggt	ccccgtggc	ccacgcctag	tgaaaatgat	3180
	atcgtccatc	tccctagaga	tatgggtcac	ctccaggtag	attacagaga	taacaggctg	3240
	cacccaagtg	aagattcttc	actggactcc	attgcctcag	ttgtggttcc	cataattata	3300
	tgctctctta	ttataatagc	attcctattc	atcaatcaga	agaaacagtg	gataccactg	3360
	ctttgctggt	atcgaacacc	aactaagcct	tcttccttaa	ataatcagct	agtatctgtg	3420
10	gactgcaaga	aaggaaccag	agtccagggt	gacagttccc	agagaatgct	aagaattgca	3480
	gaaccagatg	caagattcag	tggtctctac	agcatgcaaa	aacagaacca	tctacaggca	3540
	gacaattttct	accaaacagt	gtgaagaaag	gcaactagga	tgagggtttca	aaagacggaa	3600
	gacgactaaa	tctgctctaa	aaagtaaact	agaatttggtg	cacttgctta	gtggattgta	3660
	ttggattgtg	acttgatgta	cagcgctaag	accttactgg	gatgggctct	gtctacagca	3720
15	atgtgcagaa	caagcattcc	cacttttctc	caagataact	gaccaagtgt	tttcttagaa	3780
	ccaaagtttt	taaagttgct	aagatatatt	tgctgttaag	atagctgtag	agataattgg	3840
	gggtggggaca	gtgagtttgg	atggggaaag	gggtgggagg	gtgggtgttg	gaagaaaaat	3900
	tggtcagctt	ggctcgggga	gaaacctggt	aacataaaag	cagttcagtg	gcccagagggt	3960
	tatttttttc	ctattgctct	gaagactgca	ctgggtgctg	caaagctcag	gcctgaatga	4020
20	gcaggaaaca	aaaaaggcct	tgcgacccag	ctgccataac	caccttagaa	ctaccagacg	4080
	agcacatcag	aacctttga	cagccatccc	aggtctaaag	ccacaagttt	cttttctata	4140
	cagtcacaac	tgcagtaggc	agtgaagaa	ccagagaaat	gcgatacgcg	catttctcta	4200
	aagcgggtta	ttaaggatat	atacagttac	actttttgct	gcttttattt	gttccaaagc	4260
	caatcaatca	gccagttcct	agcagagtca	gcacatgaac	aagatctaag	tcatttcttg	4320
25	atgtgagcac	tggagctttt	tttttttaca	acgtgacagg	aagaggaggg	agagggtgac	4380
	gaacaccagg	catttccagg	ggctatatatt	cactgtttgt	tggtgctttg	ttctgttata	4440
	ttgttggttg	ttcatagttt	ttgttgaagc	tctagcttaa	gaagaaactt	tttttaaaaa	4500
	gactgttttg	ggattctttt	tccttattat	atactgattc	tacaaaaatg	aaactacttc	4560
	attttaattg	tatattattc	aagcaccttt	gttgaagctc	aaaaaaaaatg	atgcctcttt	4620
30	aaacttttagc	aattatagga	gtattttatg	aactatctta	tgcttcaaaa	aacaaaagta	4680
	tttgtgtgca	tgtgtatata	atatatatat	atacatatat	atltatacac	atacaattta	4740
	tgttttcctg	ttgaatgtat	ttttatgaga	ttttaaccag	aacaaaggca	gataaacagg	4800
	cattccatag	cagtgccttt	gatcacttac	aaattttttg	aataacacaa	aatctcattc	4860
	tacctgcagt	ttaattggaa	agatgtgtgt	gtgagagtat	gtatgtgtgt	gtgtgtgtgt	4920
35	gtgtgtgcgc	gcgcacgcac	gccttgagca	gtcagcattg	cacctgctat	ggagaagggt	4980
	attcctttat	taaaatcttc	ctcattttgga	tttgctttca	gttggttttc	aatttgctca	5040
	ctggccagag	acattgatgg	cagttcttat	ctgcatcact	aatcagctcc	tggatttttt	5100
	tttttttttt	tcaaacaatg	gtttgaaaca	actactggaa	tattgtccac	aataagctgg	5160
	aagtttggtg	tagtatgcct	caaataatac	tgactgtata	ctatagtggg	aacttttcaa	5220
40	acagccctta	gcacttttat	actaattaac	ccattttgtg	attgagtttt	cttttaaaaa	5280
	tgcttggtgt	gaaagacaca	gatacccagt	atgcttaacg	tgaaaagaaa	atgtgttctg	5340
	ttttgtaaa	gaactttcaa	gtattgttgt	aaatacttgg	acagagggtg	ctgaacttta	5400
	aaaaaaatta	atttattatt	ataatgacct	aatttattaa	tctgaagatt	aaccattttt	5460
	ttgtcttaga	atatcaaaaa	gaaaaagaaa	aaggtgttct	agctgtttgc	atcaaaggaa	5520
45	aaaaagattt	attatcaagg	ggcaatattt	ttatcttttc	caaaataaat	ttgttaatga	5580
	tacattacaa	aaatagattg	acatcagcct	gattagtata	aattttgttg	gtaattaatc	5640
	cattcctggc	ataaaaagtc	tttatcaaaa	aaaattgtag	atgcttgctt	ttgttttttt	5700
	caatcatggc	catattatga	aaatactaac	aggatatagg	acaaggtgta	aattttttta	5760
	ttattatttt	aaagatatga	tttatcctga	gtgctgtatc	tattactctt	ttacttttgt	5820
50	tctgtttgtg	ctcttgtaaa	agaaaaaatg	aatttccctga	agaataaaat	agatatatgg	5880
	cacttgaggt	gcatcatagt	tctacagttt	gtttttgttt	tcttcaaaaa	agctgtaaga	5940
	gaattatctg	caacttgatt	cttggcagga	aataaacatt	ttgagttgaa	atcaaaaaaa	6000
	aaaaaaaaaa	a					
55	<210>	34a					
	<211>	1036					
	<212>	DNA					
	<213>	Human					
60	<400>	34a					
	mylvagdrgl	agcghllvsl	lgllllpars	gtralvclpc	deskceepn	rpgsivqgvc	60
65	gccytcasgg	nescggtfgi	ygtcdrglrc	virpplngds	lteyeagvce	denwtdqll	120
	gfkpcnenli	agcniingkc	ecntirtcsn	pfefpsqdm	lsalkrieee	kpdcskarce	180
	vqfsprcped	svliegyapp	geccplpsrc	vcnpagclrk	vcqpgnlnil	vskasgkpgc	240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsncctltrk 480
 dcingfkrdh ngcrtcqcinq tqlcserkq gctlnpcpfgf ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscsthc 840
 yclqgqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgtrvqv d ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

25 gcagtagctg gagtgctctg cagggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60
 acccggggct cctgggcccgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccactgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgtattc tcttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggtagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

45 ocaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcttttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 50 gccagtaaaa accaaagtca gggttaaccaa tgctatttta caaatgtta aaacccta 300
 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaaa gctgctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aagggaacac gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttgggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
 ttcgcaccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
 tcaaaggcctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
 25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggg tcctggccca 120
 gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
 30 tggctcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
 ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
 atgtttgctt caatagaaat ttgttcccac ttgtattttc aacaaaatta tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaagt 60
 45 ctggttaggt tttgtaggct cattatgggt agggctggtt agatgtatat aagaacctac 120
 ctatcatgct gtatgtatca ctcatcccat ttcatgttc catgcatact cgggcatcat 180
 gctaatatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 50 acttccctca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420
 taagattcac tatatgtgat agtatgatag gcatttattt aaaatgcatt agactctctt 480
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
 gcttttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
 actcagaact atatttctaa gcctgcattt tcaactgatc ataattttct tagtaattatt 720
 55 aagagacagt ttttctatgg catctccaaa actgcagac atcactagtc ttacttctgc 780
 ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatttttg 840
 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
 attggattga catatgggtt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
 60 tgagatctat atttataagc agccatggaa ttctattat gggatgttgg caatcttaca 1020
 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
 gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttactc 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 tgaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatgggtg	120
	taaccccccg	ctatcagtc	ggatgggtgc	cacccctcct	gctgtaggat	ggaagcagcc	180
	atggagtg	agggagggcg	aataagacac	ccctccacag	agcttggcat	catgggaagc	240
	tggttctacc	tcttcctggc	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaagggtggag	ggtcttcatg	360
	aaacacagct	gcccaggagcc	caggcacagg	gctggggggc	tggaataagg	agggcacaca	420
15	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggctctga	aacaaggagg	480
	gcagaatagg	cagaggcctc	tccgtcccag	gcccattttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tggccgggtg	600
	gaacaagcac	aggccttgga	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
	cagccgggtg	acctgggtca	atttttagcct	ctaaaagcct	cagtctcctt	atctgcaaaa	720
20	tgaggcttgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggccatacca	ccctgaacgt	gcctaattct	gtaagctaag	cagggtcagg	840
	cctggttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgcccgcag	ttggagttgg	900
	actctgtctt	aacagtagcg	tggcacacag	aaggcactca	gtaaataact	gttgaataaa	960
	tgaagtagcg	atttggtgtg	aaaaaaa				

25

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35	cggacgggtg	ggcggacgcg	tgggtgcagg	agcagggcgg	ctgccgactg	ccccaaccaa	60
	ggaaggagcc	cctgagtc	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tgccctgtg	cagaccttac	180
	tcaggggatg	tttacctggt	gctcgggaag	ggaggggaag	gggccgggga	gggggcacgg	240
	caggcgtgtg	gcagccacac	gcaggcggcc	agggcggcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctccccoga	atgcatttgg	aaccaaagtc	taaactgagc	360
40	tgcagccccc	cgcgccctcc	ctccgcctcc	catcccgtt	agcgctctgg	acagatggac	420
	gcaggccctg	tccagccccc	agtgcgctcg	ttccggtccc	cacagactgc	cccagccaac	480
	gagattgctg	gaaaccaagt	caggccagg	gggcccagaa	aaggccagg	tgccggtgg	540
	ggggaacgga	tgtccgagg	actggactgt	ttttttcaca	catcggtgcc	gcagcgggtg	600
	gaaggaaagg	cagatgtaaa	tgatgtgttg	gtttacagg	tatatatttg	ataccttcaa	660
45	tgaattaatt	cagatgtttt	acgcaaggaa	ggacttacct	agtattactg	ctgctgtgct	720
	tttgatctct	gcttaccgtt	caagaggcgt	gtgcaggccg	acagtcggtg	accccatcac	780
	tgcagggacc	aagggggcgg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctcccttc	840
	ccttccttgg	gcagaatgaa	ttcgatgcgt	attctgtggc	cgccatctgc	gcagggtggt	900
	ggtattctgt	catttacaca	cgtcgttcta	attaaaaagc	gaattatact	ccaaaa	

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

60	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtcttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaacct	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gagcatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaattctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaactta	tttgtcaaaa	gaattagaaa	aggtgaaatg	360
	attttttcca	gatgaaactt	gtgccacttc	caattgacta	atgaaatata	aggagacaga	420
	ctggaaaaag	tgggttatgc	cacctttaaa	accctttctg	gtaaatatta	tggtagctaa	480
65	aggggtggtt	ccccggcacc	tggacctgga	caggtaggg	tccgtgggta	accagt	

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5

<400> 44

10 ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
 gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
 tctatttttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
 atccccctctg gaggggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
 ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360
 15 catggcaggt tctgggtcca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
 tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
 attaggaagt cgggggtggg tgggtgggtg gggctagttg gggttgaatt taggggccga 660
 20 tgagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtcccctt 720
 ggaaatgtcc ccttcttcag tgtcagacct cagtcaccagt gtccatatacg tgcccagaaa 780
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgccctggt 840
 gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
 tgtgattcag gtcccagggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
 25 gagttggctg gtagagcctt ctagagggtc agaatatag cttcaggatc agctgggggt 1020
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
 tgaggggacag tttgggtttg ggacttacca ggggtgatgtt agatctggaa cccccaagtg 1140
 aggtctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
 aaagagtac cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
 30 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
 tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
 actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgcctg gctgttctct 1500
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
 35 cctcttgect cttgtagaat gcagctctgg ccctcaataa atgcttctg cattcatctg 1620
 caaaaaaaaa

<210> 45
 <211> 169
 <212> DNA
 <213> Human

40

<400> 45

45 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
 taaaactggt ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga

<210> 46
 <211> 769
 <212> DNA
 <213> Human

50

<400> 46

55 tgcaggctcat atttactatc ggcaataaaa ggaagcaaa cagtattaag cagcgggtgga 60
 atttgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120
 acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180
 aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
 60 aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
 cttcatataa tgacaccaat gtctctaaat tgctcagaga tcttgactgg ctgtggccct 420
 ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
 catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
 65 tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgagggtt 600
 ttgatataat tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
 cctgcctttt tgtttttaaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
 gtgaaaatta gtgactggtt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 15 ggatgggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 gccttactta gtcctggca gagggtgagt ggggacctac gaggttcaaa atcaaatggc 360
 atttgccag cctggcttta ctaacaggtt cccagagtgc ctctgttggc tgagctctcc 420
 tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtctt ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtgcccagg aatgtttaaa atctatcagg cacactataa agctggtggt ttcttctctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg taaaaaggag aagagatggg gactgtgaag aggggagggc 840
 25 ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 gcaatagatg gggcttccca ccatttgttg gttattgctg gggttagcca ggagcagtg 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttgggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tccctacctgc ttggtacct agtccctcaa taagattcag aggaagaagc 1140
 30 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
 gaggaagac cacacaatat cattgtgctg gggctcccca aggcctgcc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440
 35 gcagttgggc tgacctgaca aagccccag tttcctgtgg caggttctgg gagaggatgc 1500
 attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagc attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 40 tgccaggaaa ccagggaagc attcaagtgt ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtg gagggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 45 tgaaaatttc cagaaatacc atttggtgca tcccttgtt tctgtaatat taaactcagg 2100
 tgaaaattata ctctgacagt ttctctctt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 50 tgcagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagattagc cagggaagcca aacaccagga gttgggggtg cagtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatatataa ggaacaatt tgcaaattha cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 65 ctagccaggc ccgttttcca tccetaagta ccattctctc atttgggccc ttctagggtt 240
 ggggccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag tgtagacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggcta tccactgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcaagcgctc ttttcttttt ttttctctga 480
 gacggagtct cgctgtgttg cccaggctgg agtgacgtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctgg attacaggcg tgagccacca cacttgccc cggcacgtat cttttaagga 780
 atgacaccag ttcttggtt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtgaagc cagcctttgg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tccttgcttg 1140
 15 ggtgctgctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200
 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgcc 1380
 tcagatcgat gtatttctct ccctggctct ccggagccct cttgtcaccg ctgctgcctc 1440
 20 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccttgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggtcagg cgggaggatt gcttgagccc aggagttaga 60
 tgttgacgtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 35 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtgg gagtgtgcaa ggtgtgtgtg gtgcccggg ggtgttcag ggcaagcatg 420
 tgcgtgcctg tgtgtgtgag tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540
 ccacgtggtt ttaaggggag acctttccct ggacctggg gtctcgcct atctcatgac 600
 40 caggtgctaa atgacccgac atgcacacc tgcctttcga tgaccaacct cctgtcccc 660
 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaatata atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgcttac aaccccttcc ttgggtccga ggctggtagc tttgttact 900
 45 tcagatggtt ggggaggggt g

<210> 50

<211> 338

<212> DNA

50 <213> Human

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tccctccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga acaaatgtc agcatgata cactactcaat gatccttctg 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaagcag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggtggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
5	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgtctgga	gacgtcctg	acaagtcggg	360
	aattttctcta	tttctccact	gggtgcaaga	goggatttct	ccctgcttct	cttctgtcac	420
	ccccgtcct	ctccccagg	aggctccttg	atztatggta	gctttggact	tgcttccccg	480
10	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gaggagagaa	tggcttctag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
15	aaaaagctga	actgcaaatc	tcaacgaagg	aaggagccat	tttaaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctaggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tggagaaagt	acagtctctg	1080
20	cttccaatac	ctctggccat	cagatgactt	taaaagggtac	aggagtaaaa	gtttaagatg	1140
	atggggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
25	<213>	Human					
	<400>	52					
30	aacagggact	ctcaactctat	caaccccagg	ctggagtccg	gtgcgcccac	cctggctccc	60
	tgcaacctcc	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	ttttttaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatacatg	cccagatgac	tttaatacct	240
	aatacaatat	atcagggttg	tttaaaaaata	attgcttttt	tattattttt	gcattttttg	300
35	accaacctta	atgctatgta	aatagttggt	atactgttgc	ttaacaacag	tatgacaatt	360
	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaacc	acagatatga	480
	agggtggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagtg	aaagttatgg	tacagtggaa	agagtagttg	aaaacataaa	catttggacc	600
40	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggtct	660
	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaaagaact	ggatactctc	taaggtcact	tccagccctg	tcattctata	780
	actctgttat	gtgaggaag	aaattcacat	tggtttaact	gtatgagtca	aactgaaaa	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aatgtgagaa	900
45	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
	agagatgggg	tctcactctg	tcacccagac	tggagtacag	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgattt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	actttattttg	1200
50	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
55	<400>	53					
60	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttatttt	60
	tatgcctttc	ttcctatgtg	tattttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgcaaggagtc	caggagacct	ctacaaatgc	180
	agagtgactc	tttaccacaa	taaaccctag	atacatgcaa	aaagcaggac	ccttcctcca	240
	ggaatgtgcc	atcttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaa	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcgaatg	cgtgatctca	ctcactgcaa	ttccacctcc	420
65	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	ggctctcgaa	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtggt	ggattacagg	atgagccacc	600

5	cgaccggcca	ctactgtctt	tctttgacct	ttccagtttc	gaagataaag	aggaaataat	660
	ttctctgaag	tacttgataa	aattttccaa	caaaacacat	gtccacttca	ctgataaaaa	720
	atttaccgca	gtttggcacc	taagagtatg	acaacagcaa	taaaaagtaa	tttcaaagag	780
	ttaagatttc	ttcagcaaaa	tagatgattc	acatcttcaa	gtcctttttg	aaatcagtta	840
	ttaatatatt	tctttcctca	tttccatctg	aatgactgca	gcaatagttt	tttttttttt	900
	tttttttttt	ttgcgagatg	gaatctcgct	ctgtcgccca	gcgggagtg	actggcgcaa	960
	gcccggctca	ccgcaatctc	tgccaccgcg				
10	<210>	54					
	<211>	250					
	<212>	DNA					
	<213>	Human					
15	<400>	54					
	catttcccca	ttggtcctga	tgttgaagat	ttagttaaag	aggctgtaag	tcaggttcga	60
	gcagaggcta	ctacaagaag	tagggaatca	agtccctcac	atgggctatt	aaaactaggt	120
	agtgggtggag	tagtgaaaaa	gaaatctgag	caacttcata	acgtaactgc	ctttcagggg	180
20	aaagggcatt	cttttaggaac	tgcattctggt	aaccacaccc	ttgatccaag	agctagggaa	240
	acttcagttg						
	<210>	55					
	<211>	2270					
25	<212>	DNA					
	<213>	Human					
	<400>	55					
30	gcgcccccca	gcagcgcccg	cgccctccgc	gccttctccg	ccgggacctc	gagcgaaaga	60
	ggccccgcgc	ccgcccagcc	ctcgctctcc	tgcccaccgc	gcacaccgcg	ccgcccaccc	120
	gaccccgctg	cgacaggcct	gtccgctgca	caccagcttg	ttggcgctct	cgctcgccgc	180
	ctcgccccgc	gctaactcctg	cgcgccacaa	tgagctcccg	catcgccagg	gcgctcgcc	240
	tagtcgtcac	ccttctccac	ttgaccaggc	tggcgctctc	cacctgcccc	gctgcctgcc	300
35	actgccccct	ggaggcgccc	aagtgcgcgc	cgggagtcgc	gctggctccg	gacggctgcg	360
	gctgctgtaa	ggctctgcgc	aagcagctca	acgaggactg	cagcaaaacg	cagccctgcg	420
	accacacca	ggggctggaa	tgcaacttcg	gcgccaagtc	caccgctctg	aaggggatct	480
	gcagagctca	gtcagagggc	agaccctgtg	aatataactc	cagaatctac	caaaacgggg	540
	aaagtttcca	gccccactgt	aaacatcagt	gcacatgtat	tgatggcgcc	gtgggctgca	600
40	ttcctctgtg	tccccaagaa	ctatctctcc	ccaacttggg	ctgtcccaac	cctcggtctg	660
	tcaaagttag	cgggcagtg	tgcgaggagt	gggtctgtga	cgaggatagt	atcaaggacc	720
	ccatggagg	ccaggacggc	ctccttgcca	aggagctggg	attcgatgcc	tccgaggttg	780
	agttgacgag	aaacaatgaa	ttgattgcag	ttggaaaagg	cagctcactg	aagcggctcc	840
	ctgttttttg	aatggagcct	cgcatcctat	acaacccttt	acaaggccag	aaatgtattg	900
45	ttcaaacaac	ttcatgggtc	cagtgtctca	agacctgtgg	aactgggtatc	tccacacgag	960
	ttaccaatga	caaccctgag	tgccgccttg	tgaaagaaac	ccggatttgt	gaggtgcggc	1020
	cttgtggaca	gccagtgtac	agcagcctga	aaaagggcaa	gaaatgcagc	aagaccaaga	1080
	aatcccccca	accagtcagg	tttacttacg	ctggatgttt	gagtggtgaa	aaataccggc	1140
	ccaagtactg	cggttctctg	gtggacggcc	gatgtgcac	gccccagctg	accaggactg	1200
50	tgaagatgcg	gttccgctgc	gaagatgggg	agacattttc	caagaacgtc	atgatgatcc	1260
	agtccctgca	atgcaactac	aactgcccgc	atgccaatga	agcagcgttt	cccttctaca	1320
	ggctgttcaa	tgacattcac	aaatttaggg	actaaatgct	acctgggttt	ccagggcaca	1380
	cctagacaaa	caaggagaaa	gagtgtcaga	atcagaatca	tgagaaaaat	ggcggggggt	1440
	ggtgtgggtg	atgggactca	ttgtagaaag	gaagccttgc	tcattcttga	ggagcattaa	1500
55	ggtatttcga	aactgccaag	ggtgctgggt	cggatggaca	ctaatagcagc	cacgattgga	1560
	gaataactttg	cttcatagta	ttggagcaca	tgttactgct	tcatttttga	gcttgtggag	1620
	ttgatgactt	tctgttttct	gtttgtaaat	tatttgctaa	gcataatttc	tctaggcttt	1680
	tttccctttg	gggttctaca	gtcgtaaaag	agataataag	attagttgga	cagtttaaag	1740
	cttttattcg	tcctttgaca	aaagtaaatg	ggagggcatt	ccatcccttc	ctgaaggggg	1800
60	acaactccatg	agtgtctgtg	agaggcagct	atctgcactc	taaactgcaa	acagaaatca	1860
	ggtgttttaa	gactgaatgt	tttattttatc	aaaatgtagc	ttttggggag	ggaggggaaa	1920
	tgtaatactg	gaataatttg	taaatgattt	taattttata	ttcagtgaaa	agattttatt	1980
	tatggaatta	accatttaat	aaagaaat	ttacctata	tctgagtgtg	tgccattcgg	2040
	tattttttaga	ggtgctccaa	agtcattagg	aacaacctag	ctcacgtact	caattattca	2100
65	aacaggactt	attgggatac	agcagtgaat	taagctatta	aaataagata	atgattgctt	2160
	ttataccttc	agtagagaaa	agtcctttgca	tataaagtaa	tgtttaaaaa	acatgtattg	2220
	aacacgacat	tgtatgaagc	acaataaaga	ttctgaagct	aaaaaaaaaa		

10	cttgaatgaa	gctgacacca	agaaccgcgg	gaagagcttg	ggcccaaagc	aggaaagggg	60
	agcgctcgag	ttggaaagga	accgctgctg	ctggccgaac	tcaagcccg	gcgccccac	120
	cagtttgatt	ggaagtccag	ctgtgaaacc	tggagcgctg	ccttctcccc	agatggctcc	180
	tggtttgctt	ggtctcaagg	acactgcac	gtcaaactga	tcccctggcc	gttggaggag	240
15	cagttcatcc	ctaaagggtt	tgaagccaaa	agccgaagta	gcaaaaatga	gacgaaaggg	300
	cggggcagcc	caaaagagaa	gacgtctggac	tgtgttcaga	ttgtctgggg	gctggccttc	360
	agcccggtgg	cttccccacc	cagcaggaag	ctctggcac	gccaccacc	ccaagtgcce	420
	gatgtctctt	gcctggttct	tgtactggga	ctcaacgatg	ggcagatcaa	gatctgggag	480
20	gtgcagacag	ggctcctgct	tttgaatctt	tccggccacc	aagatgtcgt	gagagatctg	540
	agcttcacac	ccagtggcag	tttgattttg	gtctccgcgt	cacgggataa	gactcttcgc	600
	atctggggacc	tgaataaaca	cggtaaacag	attcaagtgt	tatcgggcca	cctgcagtgg	660
	gtttactgct	gttccatctc	cccagactgc	agcatgctgt	gctctgcagc	tggagagaag	720
25	tcggtcttct	tatggagcat	gaggtcctac	acgttaattc	ggaagctaga	gggccattcaa	780
	agcagtggtg	tctcttttga	cttctcccc	gactctgcc	tgtctgtcac	ggcttcttac	840
	gataccaatg	tgattatgtg	ggacccttac	acggcgaaa	ggctgaggtc	actccaccac	900
	acccagggtg	accccgccat	ggatgacagt	gacgtccaca	ttagctcact	gagatctgtg	960
30	tgcttctctc	cagaaggctt	gtaccttgcc	acggtggcag	atgacagact	cctcaggatc	1020
	tgggcccttg	aactgaaaac	tcccattgca	tttgtccta	tgaccaatgg	gctttgctgc	1080
	acatttttct	cacatggtg	agtcatggcc	acagggacaa	gagatggcca	cgtccagttc	1140
	tgagcagctc	ctagggtcct	gtcctcactg	aagcacttat	gccggaaagc	ccttcgaagt	1200
35	ttcctaacaa	cttaaccaagt	cctagcactg	ccaatcccca	agaaaatgaa	agagttcctc	1260
	acatacagga	ctttttaagc	aacaccacat	cttgtgtctc	tttgtagcag	ggtaaatcgt	1320
	cctgtcaaag	ggagttgctg	gaataatggg	ccaacatct	gggtcttgc	tgaatatgca	1380
	tttcttttgg	attgtgaata	gaatgtagca	aaaccagatt	ccagtgtaca	taaaagaatt	1440
35	tttttgtctt	taaatagata	caaatgtcta	tcaactttaa	tcaagttgta	acttatattg	1500
	aagacaattt	gatacataat	aaaaaattat	gacaatgtcc	tgggaaaaaa	aaaatgtaga	1560
	aagatggtga	agggtgggat	ggatgaggag	cgtggtgacg	ggggcctgca	gcgggttggg	1620
	gacctgtgc	tgcgtt					

<400> 57

45	ccatgtgtgt	atgagagaga	gagagattgg	gagggagagg	gagctcacta	gcgcatatgt	60
	gcctccaggg	ggctgcagat	gtgtctgagg	gtgagcctgg	tgaaagagaa	gacaaaagaa	120
	tggaatgagc	taaagcagcc	gcctggggtg	ggaggccgag	cccatttgta	tgcagcaggg	180
	ggcaggagcc	cagcaaggga	gcctccattc	ccaggactct	ggagggagct	gagaccatcc	240
	atgcccgag	agccctccct	cacactccat	cctgtccagc	cctaattgtg	caggtgggga	300
50	aactgaggct	gggaagtcac	atagcaagtg	actggcagag	ctgggactgg	aaccaacca	360
	gcctcctaga	ccacggttct	tcccactaat	ggaatgctag	agactccagc	caggtgggta	420
	ccgagctcga	attcgtaatc	atggtcatag	ctgtttcctg			

<400> 58

60	atctgatcaa	gaatacctgc	cctggtcact	ctgcggaagt	ttctgtccac	ttgttcacat	60
	tgaggaccaa	gatatccttt	tttacagagg	cacttggttcg	gtctaacaca	gacacctcca	120
	tgacgacatg	ctggctcaca	ttttgcagtt	ctgcagaagt	ccccctccca	gcctggacta	180
	cagcagcact	ttcccgtagg	ggtagcagtag	ccgtttcgac	agagcctgga	gcactctgaa	240
65	gtcagtgtct	gtgcaggttg	taccgtggct	ctgcattcct	caggcattaa	aggctctttg	300
	ggatctacaa	ttttgtagag	ttttccattg	tgagtctggg	tcatactttt	actgcttgat	360

5 aaaatgtaaa cttcacctag ttcattctt ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgct ggagagtttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatcttttctg actggcagcc ccggtataca aatccaccaaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
 attctggctg atgatctgtt tttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaataata atgtatcata ccaaccacag taaaccaagt acaaaaaata ttcatataaa 180
 gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaag agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaattta gtagtaatag cggccgc

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/097850 A3

(51) International Patent Classification⁷: **A61K 45/06**,
A61P 35/00

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-**
tin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-**
AUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,

DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
12 December 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/097850 A3

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular
Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of
Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/EP 01/06976

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K45/06 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, CANCERLIT, EMBASE, MEDLINE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 35958 A (NOVARTIS ERFINDUNGEN VERWALTUN ;CIBA GEIGY AG (CH); TRAXLER PETER) 20 August 1998 (1998-08-20) abstract page 1, paragraph 1 ---	1-15,21
A	KOBLIZEK, THOMAS I. ET AL: "Angiopoietin-1 induces sprouting angiogenesis in vitro" CURR. BIOL. (1998), 8(9), 529-532, XP000972727 page 531, column 1, paragraph 2 --- -/--	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

15 October 2002

Date of mailing of the international search report

22/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

II International Application No
PCT/EP 01/06976

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHLAEPPI, JEAN-MARC ET AL: "Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors." CANCER AND METASTASIS REVIEWS, (1999) VOL. 18, NO. 4, PP. 473-481. PRINT., XP000972749</p> <p>page 477, column 2, paragraph 2 -page 478, column 1, paragraph 1</p> <p style="text-align: center;">-----</p>	1-21

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-16, 22

Present claims 1-16, 22 relate to compounds defined by reference to desirable characteristics or properties, namely :

- " agents which modulates the biological function of one or several of the VEGF/VEGF receptor systems",
- " agents which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems",
- " agents which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems",
- " agents which are targeted to the endothelium",
- " agents which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems",
- " agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of the Angiopoietin/Tie receptor systems",
- " compounds which inhibit receptor tyrosine kinase activity",
- " compounds which inhibit ligand binding to receptors",
- " compounds which inhibit activation of intracellular signal pathways of the receptors",
- " compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor systems",
- " delivery systems, which target cytotoxic agents or coagulation-inducing agents to the endothelium",
- " delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis",
- " compounds of general formula I, IV or V".

The claims cover all compounds having those characteristics, properties or these general formulas, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the pharmaceutical compositions mentioned in the claims 17-21, with due regard to the therapeutic applications mentioned in claim 22.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/06976

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-16, 22
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/06976

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9835958	A	20-08-1998	AU 731852 B2	05-04-2001
			AU 6621898 A	08-09-1998
			BR 9807685 A	21-03-2000
			CN 1251097 T	19-04-2000
			CZ 9902853 A3	17-11-1999
			WO 9835958 A1	20-08-1998
			EP 0970070 A1	12-01-2000
			HU 0001046 A2	28-04-2001
			JP 2001508800 T	03-07-2001
			NO 993888 A	11-10-1999
			NZ 337064 A	27-04-2001
			PL 335113 A1	10-04-2000
			SK 109699 A3	13-03-2000
			TR 9901953 T2	21-10-1999
			US 6258812 B1	10-07-2001
			US 2002091261 A1	11-07-2002
			ZA 9801155 A	13-08-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.